Search - Université Clermont Auvergne Access content directly

Filter your results

4 Results
authFullName_s : D. Nollet

Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study

Laetitia Largeaud , Pascale Cornillet-Lefebvre , Jean-François Hamel , Pierre-Yves Dumas , Naïs Prade et al.
Leukemia, 2021, 35 (5), pp.1291-1300. ⟨10.1038/s41375-020-01031-1⟩
Journal articles hal-03441014v1

Etude de phase II de l’association chemofree obinituzumab et idélalisib dans la maladie de Waldenström en rechute ou réfractaire : résultats de l’analyse intermédiaire, après la phase d’induction

C. Tomowiak , S. Chevret , S. Poulain , C. Herbaux , A. Perrot et al.
40e Congrès de la Société Française d’Hématologie, Sep 2020, Paris, France. 26 (S4), pp.135, 2020, Hématologie
Conference poster hal-02945874v1

Open Label Non-Randomized Phase II Study Exploring «Chemo-Free » Treatment Association with Idelalisib + Obinutuzumab in Patients with Relapsed/Refractory (R/R) Waldenstrom's Macroglobulinemia (MW), a Filo Trial: Results of the Intermediary Analysis of the Induction Phase

C. Tomowiak , K. Desseaux , S. Poulain , C. Herbaux , A. Perrot et al.
61st Annual Meeting and Exposition of the American Society of Hematology, Dec 2019, Orlando, United States. pp.346
Conference papers hal-02418223v1
Image document

Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study

Laetitia Largeaud , Pascale Cornillet-Lefebvre , Jean-François Hamel , Pierre-Yves Dumas , Naïs Prade et al.
Leukemia, 2021, 35 (5), pp.1291-1300. ⟨10.1038/s41375-020-01031-1⟩
Journal articles hal-03623649v1